SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix (NFLX) is trending after its latest earnings report, revealing strong ad-tier growth and expanding margins, yet the stock saw a notable decline following cautious forward guidance and the cessation of share buybacks. The community is sharply divided, with many seeing this as a prime long-term buying opportunity, while others anticipate further downside, citing the potential Warner Bros. Discovery acquisition's impact on debt and shareholder value. This pivotal moment highlights a tug-of-war between Netflix's core business strength and strategic M&A concerns.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is surging to new all-time highs, propelled by escalating geopolitical tensions stemming from recent tariff threats against European nations and discussions around Greenland. The community views this as a significant risk-off catalyst, driving substantial safe-haven inflows amid broader concerns over global stability and the dollar's future. While many anticipate further gains, calls for caution and potential profit-taking are also emerging as the metal's ascent becomes parabolic.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to multiple analyst upgrades and recent news of a significant U.S. SHIELD defense contract for chip supply, which the community views as a major catalyst. Investors are actively discussing the upcoming earnings, robust demand for server CPUs driven by AI, and the stock's notable resilience amidst broader market volatility, with many anticipating a move past key resistance levels.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of a potential acquisition by Zydus Lifesciences, sparking community speculation about a bidding war for the undervalued biotech. This is amplified by recent strong preliminary financial results, accelerated IBSRELA revenue guidance to $1 billion by 2029, and a pivotal patent extension to 2041 for both its key therapies. These developments firmly position Ardelyx as a compelling long-duration asset and an attractive target in the current biotech market landscape.

America's Oil Reserve for the Digital Age

U.S Oil

USOR Crypto is trending amidst extreme volatility, with community members fiercely debating its legitimacy as a Solana meme coin following a rapid price surge. While some anticipate significant further gains leading up to a key February 1st date, others are cautioning against a potential "rug pull" scenario, with many also discussing its inconsistent availability on various exchanges.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is currently trending following news of a significant public offering and a strategic private placement to Medtronic, exciting investors about potential validation and future prospects. The community is actively discussing the implications of this institutional investment and the concurrent start of its pivotal PARADIGM trial for the DurAVR heart valve, balancing optimism with concerns over share dilution.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid significant market uncertainty, driven by recent geopolitical rhetoric concerning Greenland and potential tariffs. While some investors anticipate a quick V-shaped rebound, others are bracing for further downside, with rising gold prices reflecting broader market anxiety. The community is actively debating whether these developments are temporary "noise" or signal a more substantial correction, especially considering underlying bond market concerns.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst significant market uncertainty driven by former President Trump's recent geopolitical rhetoric concerning Greenland and tariffs, coupled with anticipation of his upcoming Davos speech. This has spurred intense community debate, with some advocating to "buy the dip" while others voice concerns over a potential market downturn, especially as gold prices reach new all-time highs.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending due to significantly raised revenue guidance for 2026 and its strategic expansion into the space domain with a new contract win. The community is actively discussing the company's potential as a defense, AI, and robotics player, with many anticipating future government contracts and a possible short squeeze, despite some past volatility.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following its licensing deal with Pfizer for the Matrix-M adjuvant, a move seen by many as a significant validation of its platform and a potential precursor to further partnerships. The community remains highly engaged, debating the stock's high short interest and the impact of existing convertible bonds on price, alongside ongoing calls for decisive management action to unlock shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Nektar Therapeutics (NASDAQ:NKTR) Rises By 52.3%

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 2,935,715...

Nektar Therapeutics (NASDAQ:NKTR) Trading Up 6.9% - Still a Buy?

Nektar Therapeutics (NASDAQ:NKTR) Trading Up 6.9% - Here's What Happened...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar...

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for 2026.

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead

Key PointsNektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved...

Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR

Moody Aldrich Partners LLC grew its stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 62.3% in the third quarter, according to the company in its most recent Form 13F filing with the...

Simplify Asset Management Inc. Buys 35,176 Shares of Nektar Therapeutics $NKTR

Simplify Asset Management Inc. boosted its stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 67.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$36.23
Prev Close	$37.68
Open	$36.10
Dividend Yield	0.00%
50-Day Moving Average	$50.41
Beta	2.10
Avg. Volume	954,933.18
PE Ratio	-4.57

52-Week High	$66.92
52-Week Low	$6.48
Market Capitalization	$787.28M
EPS (Annual)	-$8.68
Price to Book	8.37
Revenue Per Employee	$1.61M
Enterprise Value/EBITDA	N/A

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTRNektar Therapeutics